SERCA2 activity is involved in the CNP-mediated functional responses in failing rat myocardium

British Journal of Pharmacology

Volumn 170, Issue 2, 2013, Pages 366-379

  Moltzau, L R ^a,b   Aronsen, J M ^a,b,c   Meier, S ^a,b   Nguyen, C H T ^a,b   Hougen, K ^a,b   Orstavik O ^a,b   Sjaastad, I ^a,b   Christensen, G ^a,b   Skomedal, T ^a,b   Osnes, J B ^a,b   Levy, F O ^a,b   Qvigstad, E ^a,b  

^a UNIVERSITY OF OSLO   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c BJØRKNES UNIVERSITY COLLEGE   (Norway)

Author keywords

C type natriuretic peptide; heart failure; lusitropic response; negative inotropic response; sarcoplasmatic reticulum Ca 2+ ATPase; troponin I

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 4 [2 (TRIFLUOROMETHYL)PHENYL] 3 PYRIDINECARBOXYLIC ACID METHYL ESTER; CALCIUM CHANNEL L TYPE; CALCIUM ION; CYCLIC GMP; GUANOSINE DERIVATIVE; ISOPRENALINE; NATRIURETIC PEPTIDE TYPE C; PHOSPHOLAMBAN; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SERCA2 PROTEIN; SERINE; THAPSIGARGIN; TROPONIN I; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE; GENE INACTIVATION; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; MALE; MYOFILAMENT; NEGATIVE INOTROPIC RESPONSE; NONHUMAN; POSITIVE LUSITROPIC RESPONSE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RAT; SERCA2 GENE;

C-TYPE NATRIURETIC PEPTIDE; HEART FAILURE; LUSITROPIC RESPONSE; NEGATIVE INOTROPIC RESPONSE; SARCOPLASMATIC RETICULUM CA2+ ATPASE; TROPONIN I;

3-PYRIDINECARBOXYLIC ACID, 1,4-DIHYDRO-2,6-DIMETHYL-5-NITRO-4-(2-(TRIFLUOROMETHYL)PHENYL)-, METHYL ESTER; ANIMALS; CALCIUM-BINDING PROTEINS; CYCLIC GMP; CYCLIC GMP-DEPENDENT PROTEIN KINASES; HEART FAILURE; ISOPROTERENOL; MALE; MICE; MICE, KNOCKOUT; MYOCARDIAL INFARCTION; MYOCARDIUM; MYOCYTES, CARDIAC; NATRIURETIC PEPTIDE, C-TYPE; PHOSPHORYLATION; RATS; RATS, WISTAR; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; THAPSIGARGIN; THIONUCLEOTIDES; TROPONIN I;

EID: 84883239930     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12282     Document Type: Article

References (36)

1. Alexander SPH, Mathie A, Peters JA, (2011). Guide to receptors and channels (GRAC), 5th edn. Br J Pharmacol 164 (Suppl. 1): S1-S324.
2. Andersson KB, Birkeland JA, Finsen AV, Louch WE, Sjaastad I, Wang Y, et al. (2009). Moderate heart dysfunction in mice with inducible cardiomyocyte-specific excision of the Serca2 gene. J Mol Cell Cardiol 47: 180-187.
3. Beaulieu P, Cardinal R, Page P, Francoeur F, Tremblay J, Lambert C, (1997). Positive chronotropic and inotropic effects of C-type natriuretic peptide in dogs. Am J Physiol 273: H1933-H1940.
4. Boerrigter G, Lapp H, Burnett JC, (2009). Modulation of cGMP in heart failure: a new therapeutic paradigm. Handb Exp Pharmacol 191: 485-506.
5. Bøkenes J, Aronsen JM, Birkeland JA, Henriksen UL, Louch WE, Sjaastad I, et al. (2008). Slow contractions characterize failing rat hearts. Basic Res Cardiol 103: 328-344.
6. Brusq JM, Mayoux E, Guigui L, Kirilovsky J, (1999). Effects of C-type natriuretic peptide on rat cardiac contractility. Br J Pharmacol 128: 206-212.
7. Chandra M, Dong WJ, Pan BS, Cheung HC, Solaro RJ, (1997). Effects of protein kinase A phosphorylation on signaling between cardiac troponin I and the N-terminal domain of cardiac troponin C. Biochemistry 36: 13305-13311.
8. Del Ry S, Passino C, Maltinti M, Emdin M, Giannessi D, (2005). C-type natriuretic peptide plasma levels increase in patients with chronic heart failure as a function of clinical severity. Eur J Heart Fail 7: 1145-1148.
9. Gwathmey JK, Yerevanian AI, Hajjar RJ, (2011). Cardiac gene therapy with SERCA2a: from bench to bedside. J Mol Cell Cardiol 50: 803-812.
10. Hirose M, Furukawa Y, Kurogouchi F, Nakajima K, Miyashita Y, Chiba S, (1998). C-type natriuretic peptide increases myocardial contractility and sinus rate mediated by guanylyl cyclase-linked natriuretic peptide receptors in isolated, blood-perfused dog heart preparations. J Pharmacol Exp Ther 286: 70-76.
11. Hougen K, Aronsen JM, Stokke MK, Enger U, Nygård S, Andersson KB, et al. (2010). Cre-loxP DNA recombination is possible with only minimal unspecific transcriptional changes and without cardiomyopathy in Tg(αMHC-MerCreMer) mice. Am J Physiol Heart Circ Physiol 299: H1671-H1678.
12. Kalra PR, Clague JR, Bolger AP, Anker SD, Poole-Wilson PA, Struthers AD, et al. (2003). Myocardial production of C-type natriuretic peptide in chronic heart failure. Circulation 107: 571-573.
13. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
14. Kokubun S, Reuter H, (1984). Dihydropyridine derivatives prolong the open state of Ca channels in cultured cardiac cells. Proc Natl Acad Sci U S A 81: 4824-4827.
15. Layland J, Solaro RJ, Shah AM, (2005). Regulation of cardiac contractile function by troponin I phosphorylation. Cardiovasc Res 66: 12-21.
16. Louch WE, Hougen K, Mørk HK, Swift F, Aronsen JM, Sjaastad I, et al. (2010). Sodium accumulation promotes diastolic dysfunction in end-stage heart failure following Serca2 knockout. J Physiol 588: 465-478.
17. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
18. 2+ current is regulated by cyclic GMP-dependent protein kinase in mammalian cardiac myocytes. Proc Natl Acad Sci U S A 88: 1197-1201.
19. Nir A, Zhang DF, Fixler R, Burnett JC, Jr, Eilam Y, Hasin Y, (2001). C-type natriuretic peptide has a negative inotropic effect on cardiac myocytes. Eur J Pharmacol 412: 195-201.
20. Pfitzer G, Ruegg JC, Flockerzi V, Hofmann F, (1982). cGMP-dependent protein kinase decreases calcium sensitivity of skinned cardiac fibers. FEBS Lett 149: 171-175.
21. Pierkes M, Gambaryan S, Boknik P, Lohmann SM, Schmitz W, Potthast R, et al. (2002). Increased effects of C-type natriuretic peptide on cardiac ventricular contractility and relaxation in guanylyl cyclase A-deficient mice. Cardiovasc Res 53: 852-861.
22. Potter LR, Yoder AR, Flora DR, Antos LK, Dickey DM, (2009). Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol 191: 341-366.
23. 1-adrenoceptor signalling in failing hearts through phosphodiesterase 3 inhibition. Cardiovasc Res 85: 763-772.
24. 2+-regulatory site of bovine cardiac troponin. J Biol Chem 257: 260-263.
25. Shah AM, Lewis MJ, Henderson AH, (1991). Effects of 8-bromo-cyclic GMP on contraction and on inotropic response of ferret cardiac muscle. J Mol Cell Cardiol 23: 55-64.
26. 2+ in intact cardiac myocytes. Circ Res 74: 970-978.
27. Sjaastad I, Sejersted OM, Ilebekk A, Bjørnerheim R, (2000). Echocardiographic criteria for detection of postinfarction congestive heart failure in rats. J Appl Physiol 89: 1445-1454.
28. Skomedal T, Schiander I, Aass H, Osnes JB, (1988). Properties of the inotropic response in rat papillary muscles to the dihydropyridine 'Ca-channel activator' BAY K 8644. Pharmacol Toxicol 63: 20-25.
29. Solaro RJ, Van Eyk J, (1996). Altered interactions among thin filament proteins modulate cardiac function. J Mol Cell Cardiol 28: 217-230.
30. Su J, Scholz PM, Weiss HR, (2005). Differential effects of cGMP produced by soluble and particulate guanylyl cyclase on mouse ventricular myocytes. Exp Biol Med (Maywood) 230: 242-250.
31. Wollert KC, Yurukova S, Kilic A, Begrow F, Fiedler B, Gambaryan S, et al. (2003). Increased effects of C-type natriuretic peptide on contractility and calcium regulation in murine hearts overexpressing cyclic GMP-dependent protein kinase I. Br J Pharmacol 140: 1227-1236.
32. Yasuda S, Coutu P, Sadayappan S, Robbins J, Metzger JM, (2007). Cardiac transgenic and gene transfer strategies converge to support an important role for troponin I in regulating relaxation in cardiac myocytes. Circ Res 101: 377-386.
33. Zhang Q, Moalem J, Tse J, Scholz PM, Weiss HR, (2005a). Effects of natriuretic peptides on ventricular myocyte contraction and role of cyclic GMP signaling. Eur J Pharmacol 510: 209-215.
34. Zhang Q, Scholz PM, He Y, Tse J, Weiss HR, (2005b). Cyclic GMP signaling and regulation of SERCA activity during cardiac myocyte contraction. Cell Calcium 37: 259-266.
35. Zhang Q, Scholz PM, Pilzak A, Su J, Weiss HR, (2007). Role of phospholamban in cyclic GMP mediated signaling in cardiac myocytes. Cell Physiol Biochem 20: 157-166.
36. Zhang Q, Davidov T, Weiss HR, Scholz PM, (2009). SERCA inhibition limits the functional effects of cyclic GMP in both control and hypertrophic cardiac myocytes. Pharmacology 83: 223-230.